Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status Prescription
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 0074-4456; 10019-651; 0781-6160; 12164-005; 66794-015; 66794-022; 54122-4486; 10019-653; 42677-110; 66794-012; 57884-0036; 12164-009
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cognitive disorderApoptosis regulator Bcl-2P10415T3130925774088
Cognitive disorderCaspase-3P42574T5794325774088
Cognitive disorderGlycine receptor subunit alpha-1P23415T5026925774088
Cognitive disorderApoptosis regulator BAXQ07812T8925125774088
Nerve injuryApoptosis regulator Bcl-2P49950Not Available25774088
Nerve injuryCaspase-3P42574T5794325774088
Nerve injuryApoptosis regulator BAXQ07812T8925125774088
Nerve injuryGlycine receptor subunit alpha-1P23415T5026925774088
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tonic clonic movements17.12.03.006--Not Available
Haemodynamic instability24.03.02.0060.000788%Not Available
Musculoskeletal stiffness15.03.01.0050.000788%Not Available
Transaminases increased13.03.01.0150.000788%Not Available
Haemorrhage24.07.01.0020.001182%Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.01.0190.002364%Not Available
Cardiac disorder02.01.01.003--Not Available
Lung infection22.07.01.008; 11.01.09.0080.003153%
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Pulmonary function test decreased13.19.01.001--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.0100.001970%Not Available
Unevaluable event08.01.03.0510.001576%Not Available
Increased bronchial secretion22.02.04.007--Not Available
Procedural nausea12.02.03.003; 07.01.07.0050.000788%Not Available
Procedural vomiting12.02.03.004; 07.01.07.0060.000788%Not Available
Low birth weight baby18.04.02.0030.027979%Not Available
Acute kidney injury20.01.03.016--
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000206%Not Available
Procedural haemorrhage24.07.01.053; 12.02.05.0360.002364%
Occupational exposure to product12.03.06.001--Not Available
Neonatal respiratory depression22.11.02.009; 18.04.17.0020.001182%Not Available
PCO2 increased13.02.01.0300.000788%Not Available
Holoprosencephaly17.19.01.010; 03.10.03.0070.000206%Not Available
Mitochondrial encephalomyopathy17.13.02.009; 15.05.05.014; 03.18.01.0060.001576%Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages